Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

RuBisCO Shapeshifting: Protein Adopts Multiple Assemblies

Ribulose-1,5-bisphosphate carboxylase-oxygenase (RuBisCO), the world’s most abundant protein, adopts multiple assemblies, although the origins and distribution of its different oligomeric states remain cryptic. Now, researchers show how evolution of the enzyme

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Ribulose-1,5-bisphosphate carboxylase-oxygenase (RuBisCO), the world’s most abundant protein, adopts multiple assemblies, although the origins and distribution of its different oligomeric states remain cryptic. Now, researchers show how evolution of the enzyme involved in photosynthesis can lead to a surprising diversity of molecular assemblies and that proteins can change their structural arrangement more easily than previously thought.

This work is published in Science Advances in the paper, “Structural plasticity enables evolution and innovation of RuBisCO assemblies.”

“The big finding from this paper is that there’s a lot of structural plasticity,” said Patrick Shih, PhD, assistant professor at UC Berkeley. “Proteins may be much more flexible, across the field, than we’ve believed.”

The team studied a type of RuBisCO (form II) found in bacteria and a subset of photosynthetic microbes using traditional crystallography—a technique capable of atomic-level resolution—combined with another structure-solving technique, small-angle X-ray scattering (SAXS), that has lower resolution but can take snapshots of proteins in their native form when they are in liquid mixtures. SAXS has the additional advantage of high-throughput capability.

Previous work had shown that the better-studied type of RuBisCO found in plants (form I) always takes an “octameric core” assembly of eight large protein units arranged with eight small units, whereas form II was believed to exist mostly as a dimer with a few rare examples of six-unit hexamers. After using the complementary techniques to examine samples of RuBisCO from a diverse range of microbe species, the authors observed that most form II RuBisCO proteins are actually hexamers, with the occasional dimer, and they discovered a never-before-seen tetrameric (four unit) assembly.

Combining this structural data with the respective gene sequences allowed the team to perform ancestral sequence reconstruction—a computer-based molecular evolution method that can estimate what ancestral proteins looked like based on the sequence and appearance of modern proteins that evolved from them.

The reconstruction suggests that the gene for form II RuBisCO has changed over its evolutionary history to produce proteins with a range of structures that transform into new shapes or revert back to older structures quite easily. In contrast, during the course of evolution, selective pressures led to a series of changes that locked form I RuBisCO in place (structural entrenchment) which is why the octameric assembly is the only arrangement seen. According to the authors, it was assumed that most protein assemblies were entrenched over time by selective pressure to refine their function, like we see with form I RuBisCO. But this research suggests that evolution can also favor flexible proteins.

After completing the ancestral sequence reconstruction, the team conducted mutational experiments to see how altering the rubisco assembly, in this case breaking a hexamer into a dimer, affected the enzyme’s activity. Unexpectedly, this induced mutation produced a form of RuBisCO that is better at utilizing CO2. All naturally occurring RuBisCO frequently binds the similarly sized O2 molecule on accident, lowering the enzyme’s productivity. There is a great deal of interest in genetically modifying the RuBisCO in agricultural plant species to increase the protein’s affinity for CO2, in order to produce more productive and resource-efficient crops. To this end, there has been a lot of focus on the protein’s active site.

“This is an interesting insight to us because it suggests that in order to have more fruitful results engineering RuBisCO, we can’t just look at the simplest answer, the region of the enzyme that actually interacts with CO2,” said Albert Liu, a graduate student in Shih’s lab. “Maybe there are mutations outside of that active site that actually participate in this activity and can potentially change protein function in a way that we want. So that’s something that really opens doors to future avenues of research.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →